Children, adolescents & young adults
Why Age-Appropriate Psychosis Care Matters
Psychosis can interrupt development at an important time in a young person’s life. Assessment and treatment should reflect their age, learning needs, family circumstances, and goals.[1,2]
Continue to key pointsReasons consultation matters for children, adolescents, and young adults
Symptoms must be understood in the context of development
A young person’s developmental history, learning and communication needs, and changes from their usual behavior help make sense of symptoms. Assessment should consider these alongside mood, substance use, and medical conditions.[1,2]
Treatment should address symptoms while protecting physical health
Medication choices and monitoring should reflect the young person’s age and needs. Weight gain and other side effects deserve attention early, alongside whether treatment is helping.[1,2,3]
School, relationships, and growing independence matter
Difficulties with attention, memory, or learning can affect school and everyday activities. Treatment planning should consider these needs alongside friendships, work, and the young person’s goals for independence. This includes preparing for college or a move to adult services.[1,2,4]
Families bring important context and support
Parents and caregivers can help explain the young person’s development, strengths, and changes at home or school. Hearing their observations alongside the young person’s experience helps build a shared understanding and a plan that supports growing independence. Family involvement should reflect the young person’s age, preferences, and privacy.[1,2]
Evidence snapshot
Learning needs deserve attention alongside symptoms
Young people with schizophrenia may have difficulties with attention, memory, or learning.[4] Recognizing these needs is important when planning support for school and everyday life.
How our consultation can help
Our one-time consultation brings together developmental history, current symptoms, and the young person’s goals to offer age-appropriate recommendations for the patient, family, and treating clinician.
References
- National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Clinical guideline CG155. 2013; updated 2016.
- National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. 2014.
- Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-73.
- Hooper SR, Giuliano AJ, Youngstrom EA, Breiger D, Sikich L, Frazier JA, et al. Neurocognition in early-onset schizophrenia and schizoaffective disorders. J Am Acad Child Adolesc Psychiatry. 2010;49(1):52-60.
